Xiaotong Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaotong Tian has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Ying Ge
Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing
2 shared publications- Zhengyin Liu
Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
2 shared publications BaoTong Zhou
Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing
1 shared publication- Chenjie Hu
Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China
1 shared publication - Guoqiang Sun
Information Center, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
1 shared publication - Hongpu Hu
Institute of Medical Information/Medical Library, Chinese Academy of Medical Sciences & Peking Union Medical College, China
1 shared publication
Latest Publications
- Open Access
- 22 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Long-Term Follow-Up of Patients With Classic Fever of Unknown Origin: Prognostic Outcomes and Management Strategies
Background: This study evaluates the long-term prognosis of patients with classic fever of unknown origin (FUO) who are discharged without a definitive diagnosis, enhances the understanding of FUO, and provides evidence-based guidance for its diagnosis and management. Method: A retrospective analysis was conducted on hospitalized patients at the Department of Infectious Diseases, Peking Union Medical College Hospital, who met the diagnostic criteria for classic FUO. Clinical characteristics and diagnostic outcomes were summarized, and patients without a definitive diagnosis (including those classified as clinical and indeterminate diagnoses) were examined longitudinally to determine their prognostic outcomes. Results: Overall, 739 patients with classic FUO were included. At discharge, 36.8% (n = 272) received a definitive etiologic diagnosis, 48.8% (n = 361) had a clinical diagnosis, and 14.3% (n = 106) remained indeterminate. Median hospitalization cost was significantly higher in the definitive diagnosis than in the clinical diagnosis group {22 000 RMB (interquartile range [IQR] 14 000–37 000) vs 17 000 RMB (IQR 11 000–29 000); P < .001}. Among 396 successfully followed-up patients discharged without a definitive diagnosis, mortality rate was 3.3% (13/396). During follow-up, 289 patients (73.0%) received a definitive diagnosis. The concordance rate between discharge and follow-up diagnoses was 93.0%, and the success rate of diagnostic antituberculosis therapy was 79.1% (53/67). Among the undiagnosed patients, 31.8% (34/107) experienced spontaneous remission, and 36.4% (39/107) achieved remission after short-term anti-inflammatory therapy. Conclusions: Most patients with classic FUO without a definitive diagnosis have a favorable prognosis, suggesting avoiding overtreatment. This study underscores the value of diagnostic therapies and close follow-up as key strategies in clinical management.
- 22 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Open AccessLong-Term Follow-Up of Patients With Classic Fever of Unknown Origin: Prognostic Outcomes and Management Strategies
Background: This study evaluates the long-term prognosis of patients with classic fever of unknown origin (FUO) who are discharged without a definitive diagnosis, enhances the understanding of FUO, and provides evidence-based guidance for its diagnosis and management. Method: A retrospective analysis was conducted on hospitalized patients at the Department of Infectious Diseases, Peking Union Medical College Hospital, who met the diagnostic criteria for classic FUO. Clinical characteristics and diagnostic outcomes were summarized, and patients without a definitive diagnosis (including those classified as clinical and indeterminate diagnoses) were examined longitudinally to determine their prognostic outcomes. Results: Overall, 739 patients with classic FUO were included. At discharge, 36.8% (n = 272) received a definitive etiologic diagnosis, 48.8% (n = 361) had a clinical diagnosis, and 14.3% (n = 106) remained indeterminate. Median hospitalization cost was significantly higher in the definitive diagnosis than in the clinical diagnosis group {22 000 RMB (interquartile range [IQR] 14 000–37 000) vs 17 000 RMB (IQR 11 000–29 000); P < .001}. Among 396 successfully followed-up patients discharged without a definitive diagnosis, mortality rate was 3.3% (13/396). During follow-up, 289 patients (73.0%) received a definitive diagnosis. The concordance rate between discharge and follow-up diagnoses was 93.0%, and the success rate of diagnostic antituberculosis therapy was 79.1% (53/67). Among the undiagnosed patients, 31.8% (34/107) experienced spontaneous remission, and 36.4% (39/107) achieved remission after short-term anti-inflammatory therapy. Conclusions: Most patients with classic FUO without a definitive diagnosis have a favorable prognosis, suggesting avoiding overtreatment. This study underscores the value of diagnostic therapies and close follow-up as key strategies in clinical management.
- Open Access
- 22 November 2024
- Published by Association for Computing Machinery (ACM)
- p. 325-331
Construction of Early Warning Mechanism and Application Model of Electronic Health Prescriptions for Brucella Infection Patients
- 22 November 2024
- Published by Association for Computing Machinery (ACM)
- p. 325-331
Open AccessConstruction of Early Warning Mechanism and Application Model of Electronic Health Prescriptions for Brucella Infection Patients
- Open Access
- 1 October 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 4403-4415
Optimizing Treatment Strategies for Carbapenem-Resistant Acinetobacter Baumannii-Associated Pneumonia: A Multicenter Study in Chinese Hospitals
Purpose: To evaluate the clinical outcomes and safety of tigecycline (TGC) plus cefoperazone/sulbactam (CPS) or TGC monotherapy in patients with hospital-acquired pneumonia (HAP) caused by Carbapenem-Resistant Acinetobacter baumannii (CRAB). Methods: This was a retrospective analysis of multicenter data from 62 Chinese hospitals with CRAB HAP. Risk factors for receiving TGC with CPS therapy and predictors of mortality were assessed using multivariate logistic and Cox regression analyses, respectively. Propensity score matching (PSM) evaluated the efficacy and safety of antimicrobial regimens. Results: A total of the 180 patients were included, with 95 receiving TGC monotherapy and 85 receiving combination therapy. Multivariate logistic regression analysis revealed that older age (P = 0.011), and intensive care unit (ICU) admission (P = 0.007) were significant risk factors for combination therapy. Multivariate Cox regression demonstrated that combination therapy was associated with a significantly higher risk of 90-day mortality (P = 0.031). Patients in the standard-dose TGC (SDT) plus CPS subgroup had significantly higher rates of SOFA scores ≥ 7 (P = 0.009) and MV used (P = 0.028), as well as higher 30-/90-day mortality compared to high-dose TGC (HDT) plus CPS group. TGC plus CPS significantly reduced CRP levels (P = 0.009), while the variations in ALT, TBIL, Cr, Hb, and PLT levels did not differ between different antimicrobial regimens after PSM. Conclusion: HDT and CPS combination therapy was more effective in patients with advanced age and more severe condition. Safety profiles of different antimicrobial regimens were similar with liver, kidneys, and coagulation functions.
- 1 October 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 4403-4415
Open AccessOptimizing Treatment Strategies for Carbapenem-Resistant Acinetobacter Baumannii-Associated Pneumonia: A Multicenter Study in Chinese Hospitals
Purpose: To evaluate the clinical outcomes and safety of tigecycline (TGC) plus cefoperazone/sulbactam (CPS) or TGC monotherapy in patients with hospital-acquired pneumonia (HAP) caused by Carbapenem-Resistant Acinetobacter baumannii (CRAB). Methods: This was a retrospective analysis of multicenter data from 62 Chinese hospitals with CRAB HAP. Risk factors for receiving TGC with CPS therapy and predictors of mortality were assessed using multivariate logistic and Cox regression analyses, respectively. Propensity score matching (PSM) evaluated the efficacy and safety of antimicrobial regimens. Results: A total of the 180 patients were included, with 95 receiving TGC monotherapy and 85 receiving combination therapy. Multivariate logistic regression analysis revealed that older age (P = 0.011), and intensive care unit (ICU) admission (P = 0.007) were significant risk factors for combination therapy. Multivariate Cox regression demonstrated that combination therapy was associated with a significantly higher risk of 90-day mortality (P = 0.031). Patients in the standard-dose TGC (SDT) plus CPS subgroup had significantly higher rates of SOFA scores ≥ 7 (P = 0.009) and MV used (P = 0.028), as well as higher 30-/90-day mortality compared to high-dose TGC (HDT) plus CPS group. TGC plus CPS significantly reduced CRP levels (P = 0.009), while the variations in ALT, TBIL, Cr, Hb, and PLT levels did not differ between different antimicrobial regimens after PSM. Conclusion: HDT and CPS combination therapy was more effective in patients with advanced age and more severe condition. Safety profiles of different antimicrobial regimens were similar with liver, kidneys, and coagulation functions.